Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q2 2024 Earnings Conference
Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q2 2024 Earnings Conference
ARCALYST collaboration operating profit grew 114% year-over-year to $59.9 million.The following is a summary of the Kiniksa Pharmaceuticals International, Plc (KNSA) Q2 2024 Earnings Call Transcript:
以下是Kiniksa Pharmaceuticals International, Plc (KNSA) 2024年第二季度業績會交流會議摘要：
Financial Performance:
金融業績：
Kiniksa reported Q2 2024 total revenue of $108.6 million, including $103.4 million from ARCALYST, reflecting a 90% year-over-year growth.
Net loss for Q2 2024 was $3.9 million compared to net income of $15 million in Q2 2023.
ARCALYST collaboration operating profit grew 114% year-over-year to $59.9 million.
Anticipate a full year 2024 net sales guidance adjustment to $405 million to $415 million.
Kiniksa報告2024年第二季度總營業收入爲10860萬美元，包括來自ARCALYSt的10340萬美元，同比增長90%。
2024年Q2淨虧損爲390萬美元，而2023年Q2淨利潤爲1500萬美元。
ARCALYSt合作伙伴營業利潤同比增長114%至5990萬美元。
預計全年2024年淨銷售業績指引爲40500萬-41500萬美元。
Business Progress:
業務進展：
Continued strong commercial performance of ARCALYST in recurrent pericarditis, reaching an 11% penetration into the target patient population.
Invested in sales force expansion and partnerships including with the American Heart Association and Henrik Lundqvist for disease awareness.
Initiated a Phase 2b study of abiprubart in Sjögren's Disease, aiming to address the unmet medical needs in autoimmune diseases.
ARCALYSt在反覆性心包炎方面持續表現強勁，目標患者群體滲透率達11%。
投資於拓展銷售團隊和合作夥伴，包括美國心臟協會和Henrik Lundqvist以提高疾病認知。
啓動Sjögren's Disease的abiprubart二期20億研究，旨在解決自身免疫性疾病的未滿足醫療需求。
Opportunities:
機會：
Expanded ARCALYST treatment to a broader recurrence population, providing growth potential.
Enhanced marketing strategies and physician education to solidify ARCALYST as the standard therapy.
將ARCALYSt治療拓展至更廣泛的復發人群，提供增長潛力。
加強營銷策略和醫生教育，鞏固ARCALYSt作爲標準治療。
Risks:
風險：
Acknowledges the gradual adaptation by prescribers and payers to recognize and treat recurrent pericarditis as a chronic condition could affect the pace of growth.
承認處方者和支付者逐漸適應認識和治療反覆性心包炎作爲慢性病的步伐可能會影響增長速度。
More details: Kiniksa Pharmaceuticals International IR
更多詳情請參閱Kiniksa Pharmaceuticals International IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。